Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 9/20 | 0.48 |
| ▸ | IGF1R | P08069 | 3/20 | 0.47 |
| ▸ | JAK3 | P52333 | 2/20 | 0.43 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.42 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
| ▸ | CDK9 | P50750 | 1/20 | 0.42 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 4/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.39 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26384116 | 0.90 | IGF1R (0.56) | NTRK1IGF1RJAK3CCNT1CCNE1 | |
| SCHEMBL26397057 | 0.87 | EGFR (0.47) | NTRK1IGF1RJAK3CDK2PTK2 | |
| SCHEMBL26397384 | 0.86 | EGFR (0.46) | EGFRJAK2 | |
| SCHEMBL26383818 | 0.86 | EGFR (0.46) | EGFRJAK2 | |
| SCHEMBL26395904 | 0.84 | LRRK2 (0.56) | EGFRJAK2 | |
| SCHEMBL26384130 | 0.83 | EGFR (0.51) | EGFRJAK2 | |
| SCHEMBL26379137 | 0.80 | IGF1R (0.55) | NTRK1IGF1RJAK3CCNT1CCNE1 | |
| SCHEMBL26384176 | 0.80 | EGFR (0.49) | NTRK1IGF1RJAK3EGFRJAK2 | |
| SCHEMBL26383894 | 0.79 | IGF1R (0.40) | IGF1REGFR | |
| SCHEMBL26384067 | 0.78 | EGFR (0.59) | NTRK1JAK3EGFRJAK2NTRK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230310428-A1 | EGFR INHIBITOR AND PREPARATION METHOD AND USE THEREOF | Hongyun Biotech Co., Ltd. (CN) | 2023-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230310428-A1 | EGFR INHIBITOR AND PREPARATION METHOD AND USE THEREOF | EGFR, ERBB2, ERBB4 | NTRK1 195/4885IGF1R 73/4885JAK3 115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.